No Data
No Data
Soligenix Repays Loan, Boosting Financial Flexibility
Express News | Soligenix Inc - on Feb 5, Repays and Terminates Loan Agreement With Pontifax Medison
Soligenix on Way to Bio Conference in NYC
Soligenix Shares Are Trading Higher After the Company Announced Interim Data From Its Investigator-initiated Study of HyBryte for Early-stage Cutaneous T-cell Lymphoma, Which Showed Over 70% of Patients Who Completed at Least 18 Weeks of Therapy...
Express News | Hybryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
EXCLUSIVE: Soligenix Tells Benzinga 'Patients Have Responded Positively to HyBryte Therapy, With Over 70% (5 of the 6 Subjects Who Have Completed at Least 18 Weeks of Therapy) Already Achieving "Treatment Success'